PHASE II TRIAL OF IV SODIUM PHENYLACETATE IN B CELL CLL

本研究的目的是1）了解药物，钠， 苯乙酸钠（NaPA），对慢性淋巴细胞白血病有帮助 和非霍奇金淋巴瘤，2）观察药物的副作用 原因是在持续的时间内。 本研究通过持续输注使用苯乙酸钠（NaPA） 对于复发性非霍奇金淋巴瘤患者，持续6个月， 骨髓瘤和慢性淋巴细胞白血病。 我们发现了一种药物 一旦患者达到最佳剂量， 药 急性副作用包括嗜睡、耳鸣和 听力下降和恶心 这些都是剂量相关的， 在药物保存后24 - 48小时内。 并无其他 显著的器官毒性，并且药物不是骨髓抑制性的。 目前的计划是提出这类药物的额外试验 与常规化疗剂联合。 书 意图正在形成。

The goals of this research study are 1) to learn if the drug, sodium phenylacetate (NaPA), is helpful against chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and 2) to look at the side effects the drug causes when given over continued periods of time. This study utilizes sodium phenylacetate (NaPA) by continuous infusion for 6 months for patients with relapsed non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. We have found the drug to be well-tolerated once the patient has achieved the optimal dose of the drug. Acute side effects have consisted of somnolence, tinnitis and decreased hearing, and nausea. These are dose-related and resolve within 24-48 hours after the drug is held. There have been no other significant organ toxicities and the drug is not myelosuppressive. Current plans are to propose additional trials of this class of drugs in combination with conventional chemotherapy agents. A Letter of Intent is being formulated.